Get the Stockscreener App
0.389
0.36%
0.0014
Fibrogen Inc Stock (FGEN) Latest News
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN) - Defense World
ARMISTICE CAPITAL, LLC Reduces Stake in FibroGen Inc - GuruFocus.com
FibroGen Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
FGEN stock touches 52-week low at $0.19 amid market challenges - Investing.com India
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: FibroGen reports strong Q3 sales, advances in oncology pipeline - Investing.com UK
FibroGen: Q3 Earnings Snapshot - mySA
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - MSN
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions By GuruFocus - Investing.com Canada
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions - Yahoo Finance
FibroGen Reports Strong Q3 Growth and Future Plans - TipRanks
FibroGen Inc earnings beat by $0.14, revenue topped estimates - Investing.com Australia
FibroGen Inc (FGEN) Q3 2024 Earnings: Revenue Surges to $46.3M, EPS at $(0.17), Exceeding Estimates - GuruFocus.com
FibroGen Reports Third Quarter 2024 Financial Results - GlobeNewswire
FibroGen Q3 Revenue Surges 15% as China Sales Soar; Narrows Net Loss by 73% | FGEN Stock News - StockTitan
FibroGen Inc (FGEN) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewswire
FibroGen Names Dr. Deyaa Adib As SVP And Chief Medical Officer - Contract Pharma
Metrics That Matter About FibroGen Inc (NASDAQ: FGEN) - Stocks Register
FGEN stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding - Simply Wall St
FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
FGEN stock touches 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com - Defense World
The growth track for FibroGen Inc (FGEN) has changed recently - SETE News
Should investors be concerned about FibroGen Inc (FGEN)? - US Post News
Cubist Systematic Strategies LLC Has $256,000 Stock Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Market Watch: FibroGen Inc (FGEN)’s Noteworthy Gain, Closing at 0.36 - The Dwinnex
FibroGen Hits New 52-week High, What's Fuelling The Stock? - RTTNews
Pulmonary Fibrosis Drug Market Size & Analysis By 2024 -2034 -Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., – IndiaPolitics.com - IndiaPolitics.com
Sei Investments Co. Purchases 41,442 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Financial Review: FibroGen (NASDAQ:FGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) - Defense World
FibroGen's US$6.2m Market Cap Fall Books Insider Losses - Simply Wall St
FibroGen Inc [FGEN] Chief Medical Officer makes an insider acquire of 22,123 shares worth 25,884. - Knox Daily
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts - Yahoo Finance
Investors in cash trouble should check out FibroGen Inc (FGEN) - SETE News
FGEN stock touches 52-week low at $0.33 amid market challenges By Investing.com - Investing.com South Africa
FGEN stock touches 52-week low at $0.33 amid market challenges - Investing.com Australia
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):